Leveraging Mobile Health Technology to Optimize Early Stimulant Medication Treatment: A Feasibility Pilot
Status: | Active, not recruiting |
---|---|
Conditions: | Neurology, Psychiatric |
Therapuetic Areas: | Neurology, Psychiatry / Psychology |
Healthy: | No |
Age Range: | 5 - 12 |
Updated: | 1/27/2019 |
Start Date: | January 2014 |
End Date: | December 2020 |
The goal of this study is to develop and test a mobile web application to optimize early
stimulant medication treatment for children receiving care for Attention/Deficit
Hyperactivity Disorder (ADHD) in a publicly-funded mental health clinic.
stimulant medication treatment for children receiving care for Attention/Deficit
Hyperactivity Disorder (ADHD) in a publicly-funded mental health clinic.
In other words, the study will find out whether it is feasible and acceptable for parents to
receive reminders for clinic visits and ADHD medication and enter daily ratings of their
child's ADHD symptoms and medication side effects into a smart phone. It will also examine
whether it is feasible and acceptable for doctors to use this information summarized on a
tablet (iPad) screen during a medication follow-up visit. If the parent consents, the study
will also examine whether it is feasible and acceptable for the child's teacher to enter
their ratings of ADHD symptoms twice a week using a link on their email. This information
will also be included in the doctor's iPad screen. If this technology is found to be
promising, then a larger study will be done to examine if medication treatment is safer, more
consistent, and more effective using this technology compared to usual care. This is
important because the technology may remove the burden on parents and teachers to report ADHD
symptoms and medication side effects using paper forms, and for doctors to record this
information in the medical record. In total, there will be 12 parent/ child dyads, 6
clinicians and up to 12 teachers enrolled. Each parent/child dyad will be videotaped for up
to 3 visits with the clinician (n=36 videotaped sessions). The study time period is from the
first visit that ADHD medication is prescribed to the time of the third follow-up medication
visit. We anticipate that the follow-up visits will be every 1-2 weeks during this early
phase of stimulant medication treatment. Thus, the study time period for each parent/child
dyad will be between 4-8 weeks. We anticipate that data collection will occur between August
19, 2013 and June 31, 2014.
receive reminders for clinic visits and ADHD medication and enter daily ratings of their
child's ADHD symptoms and medication side effects into a smart phone. It will also examine
whether it is feasible and acceptable for doctors to use this information summarized on a
tablet (iPad) screen during a medication follow-up visit. If the parent consents, the study
will also examine whether it is feasible and acceptable for the child's teacher to enter
their ratings of ADHD symptoms twice a week using a link on their email. This information
will also be included in the doctor's iPad screen. If this technology is found to be
promising, then a larger study will be done to examine if medication treatment is safer, more
consistent, and more effective using this technology compared to usual care. This is
important because the technology may remove the burden on parents and teachers to report ADHD
symptoms and medication side effects using paper forms, and for doctors to record this
information in the medical record. In total, there will be 12 parent/ child dyads, 6
clinicians and up to 12 teachers enrolled. Each parent/child dyad will be videotaped for up
to 3 visits with the clinician (n=36 videotaped sessions). The study time period is from the
first visit that ADHD medication is prescribed to the time of the third follow-up medication
visit. We anticipate that the follow-up visits will be every 1-2 weeks during this early
phase of stimulant medication treatment. Thus, the study time period for each parent/child
dyad will be between 4-8 weeks. We anticipate that data collection will occur between August
19, 2013 and June 31, 2014.
Inclusion Criteria:
- parent's and child's primary language is English or Spanish
- child is between 5-11 years
- child received a clinical diagnosis of ADHD
- child is receiving stimulant medication for the first time
- child does not take any other medication on a regular basis (like every day)
Exclusion Criteria:
- any chronic medical condition that requires on-going medication management
- prescription of combined psychotropic medication
- moderate-severe developmental delays, mental retardation or autism
We found this trial at
3
sites
9650 Zelzah Avenue
Northridge, California 91325
Northridge, California 91325
Phone: 818-739-5763
Click here to add this to my saved trials
Los Angeles, California 90059
Principal Investigator: Bonnie Zima, MD, MPH
Phone: 310-668-4272
Click here to add this to my saved trials
200 Medical Plaza Driveway
Los Angeles, California 90095
Los Angeles, California 90095
Phone: 310-917-3376
Click here to add this to my saved trials